BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 31553054)

  • 1. Changing Body Weight-Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma.
    Novakovic AM; Wilkins JJ; Dai H; Wade JR; Neuteboom B; Brar S; Bello CL; Girard P; Khandelwal A
    Clin Pharmacol Ther; 2020 Mar; 107(3):588-596. PubMed ID: 31553054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model-informed drug development supporting the approval of the avelumab flat-dose regimen in patients with advanced renal cell carcinoma.
    Masters JC; Khandelwal A; di Pietro A; Dai H; Brar S
    CPT Pharmacometrics Syst Pharmacol; 2022 Apr; 11(4):458-468. PubMed ID: 35166465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Avelumab: A Review of Its Application in Metastatic Merkel Cell Carcinoma.
    Joseph J; Zobniw C; Davis J; Anderson J; Trinh VA
    Ann Pharmacother; 2018 Sep; 52(9):928-935. PubMed ID: 29616562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial.
    Lambert J; Marrel A; D'Angelo SP; Burgess MA; Chmielowski B; Fazio N; Gambichler T; Grob JJ; Lebbé C; Robert C; Russell J; Güzel G; Bharmal M
    Patient; 2020 Aug; 13(4):457-467. PubMed ID: 32472503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.
    D'Angelo SP; Bhatia S; Brohl AS; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Georges S; Shah P; Ellers-Lenz B; Bajars M; Güzel G; Nghiem PT
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avelumab for the treatment of metastatic Merkel cell carcinoma.
    Cordes LM; Gulley JL
    Drugs Today (Barc); 2017 Jul; 53(7):377-383. PubMed ID: 28837181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avelumab: A Novel Anti-PD-L1 Agent in the Treatment of Merkel Cell Carcinoma and Urothelial Cell Carcinoma.
    Teets A; Pham L; Tran EL; Hochmuth L; Deshmukh R
    Crit Rev Immunol; 2018; 38(3):159-206. PubMed ID: 30004857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world clinical outcomes with first-line avelumab in locally advanced/metastatic Merkel cell carcinoma in the USA: SPEAR-Merkel.
    Cowey CL; Liu FX; Kim R; Boyd M; Fulcher N; Krulewicz S; Kasturi V; Bhanegaonkar A
    Future Oncol; 2021 Jun; 17(18):2339-2350. PubMed ID: 33709776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial.
    D'Angelo SP; Russell J; Lebbé C; Chmielowski B; Gambichler T; Grob JJ; Kiecker F; Rabinowits G; Terheyden P; Zwiener I; Bajars M; Hennessy M; Kaufman HL
    JAMA Oncol; 2018 Sep; 4(9):e180077. PubMed ID: 29566106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting.
    Morrissey KM; Marchand M; Patel H; Zhang R; Wu B; Phyllis Chan H; Mecke A; Girish S; Jin JY; Winter HR; Bruno R
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1257-1267. PubMed ID: 31542806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East.
    Ascierto PA; Orlova K; Grignani G; Dudzisz-Śledź M; Fenig E; Chiarion Sileni V; Fazio N; Samimi M; Mortier L; Gebhardt C; Kramkimel N; Steven N; Bechter O; Arance A; Benincasa E; Kostkova L; Costa N; Lorigan P
    Int J Cancer; 2021 Dec; 149(11):1926-1934. PubMed ID: 34310716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study.
    D'Angelo SP; Lebbé C; Mortier L; Brohl AS; Fazio N; Grob JJ; Prinzi N; Hanna GJ; Hassel JC; Kiecker F; von Heydebreck A; Güzel G; Nghiem P
    ESMO Open; 2024 May; 9(5):103461. PubMed ID: 38744102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time-Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma.
    Wilkins JJ; Brockhaus B; Dai H; Vugmeyster Y; White JT; Brar S; Bello CL; Neuteboom B; Wade JR; Girard P; Khandelwal A
    CPT Pharmacometrics Syst Pharmacol; 2019 Jun; 8(6):415-427. PubMed ID: 30980481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.
    Kaufman HL; Russell J; Hamid O; Bhatia S; Terheyden P; D'Angelo SP; Shih KC; Lebbé C; Linette GP; Milella M; Brownell I; Lewis KD; Lorch JH; Chin K; Mahnke L; von Heydebreck A; Cuillerot JM; Nghiem P
    Lancet Oncol; 2016 Oct; 17(10):1374-1385. PubMed ID: 27592805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program.
    Walker JW; Lebbé C; Grignani G; Nathan P; Dirix L; Fenig E; Ascierto PA; Sandhu S; Munhoz R; Benincasa E; Flaskett S; Reed J; Engelsberg A; Hariharan S; Kasturi V
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32269140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cost-utility analysis of avelumab for metastatic Merkel cell carcinoma in Taiwan.
    Chang WC; Lin AY; Hsu JC; Wu CE; Goh C; Chou P; Kuo K; Chang A; Palencia R
    Cancer Rep (Hoboken); 2021 Dec; 4(6):e1399. PubMed ID: 33934577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.
    Kaufman HL; Russell JS; Hamid O; Bhatia S; Terheyden P; D'Angelo SP; Shih KC; Lebbé C; Milella M; Brownell I; Lewis KD; Lorch JH; von Heydebreck A; Hennessy M; Nghiem P
    J Immunother Cancer; 2018 Jan; 6(1):7. PubMed ID: 29347993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program.
    Grignani G; Chiarion Sileni V; Pinto C; Depenni R; Fazio N; Galli L; Giuffrida D; Carnaghi C; Ciliberto D; Corsi DC; Queirolo P; Benincasa E; Venturini F; Fazzi G; Costa N; Ascierto PA
    J Transl Med; 2021 Feb; 19(1):70. PubMed ID: 33588870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of dosing strategy for pembrolizumab for oncology indications.
    Freshwater T; Kondic A; Ahamadi M; Li CH; de Greef R; de Alwis D; Stone JA
    J Immunother Cancer; 2017; 5():43. PubMed ID: 28515943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study.
    D'Angelo SP; Lebbé C; Mortier L; Brohl AS; Fazio N; Grob JJ; Prinzi N; Hanna GJ; Hassel JC; Kiecker F; Georges S; Ellers-Lenz B; Shah P; Güzel G; Nghiem P
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34301810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.